Basit öğe kaydını göster

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

dc.contributor.authorKwong, Ava
dc.contributor.authorTibau, Ariadna
dc.contributor.authorKuemmel, Sherko
dc.contributor.authorCampone, Mario
dc.contributor.authorLoirat, Delphine
dc.contributor.authorLopez Lopez, Rafael
dc.contributor.authorBeck, J. Thaddeus
dc.contributor.authorDe Laurentiis, Michelino
dc.contributor.authorIm, Seock-Ah
dc.contributor.authorKim, Sung-Bae
dc.contributor.authorSteger, Guenther G.
dc.contributor.authorAdelantado, Esther Zamora
dc.contributor.authorDuhoux, Francois P.
dc.contributor.authorGreil, Richard
dc.contributor.authorKuter, Irene
dc.contributor.authorLu, Yen-Shen
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorScholz, Christian W.
dc.contributor.authorSinger, Christian F.
dc.contributor.authorVega, Estela
dc.contributor.authorWimberger, Pauline
dc.contributor.authorZamagni, Claudio
dc.contributor.authorCouillebault, Xuan-Mai
dc.contributor.authorFan, Liqiong
dc.contributor.authorGuerreiro, Nelson
dc.contributor.authorMataraza, Jennifer
dc.contributor.authorSand-Dejmek, Janna
dc.contributor.authorChan, Arlene
dc.date.accessioned2022-07-04T15:24:34Z
dc.date.available2022-07-04T15:24:34Z
dc.date.issued2022
dc.identifier.citationKuemmel S., Campone M., Loirat D., Lopez Lopez R., Beck J. T. , De Laurentiis M., Im S., Kim S., Kwong A., Steger G. G. , et al., "A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer", CLINICAL CANCER RESEARCH, cilt.28, sa.1, ss.106-115, 2022
dc.identifier.issn1078-0432
dc.identifier.othervv_1032021
dc.identifier.otherav_adc806f7-4501-490d-86ba-133c06b0b1ae
dc.identifier.urihttp://hdl.handle.net/20.500.12627/184217
dc.identifier.urihttps://doi.org/10.1158/1078-0432.ccr-20-3955
dc.description.abstractPurpose: This phase II study determined the efficacy of lacnotuzumab added to gemcitabine plus carboplatin (gem-carbo) in patients with advanced triple-negative breast cancer (TNBC).
dc.language.isoeng
dc.subjectOnkoloji
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOncology
dc.subjectHealth Sciences
dc.titleA Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
dc.typeMakale
dc.relation.journalCLINICAL CANCER RESEARCH
dc.contributor.departmentHosp Santa Creu & Sant Pau , ,
dc.identifier.volume28
dc.identifier.issue1
dc.identifier.startpage106
dc.identifier.endpage115
dc.contributor.firstauthorID3391636


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster